Rituximab in lymphocyte-predominant Hodgkin disease

Hatem A. Azim, Giancarlo Pruneri, Emilia Cocorocchio, Saverio Cinieri, Paola R. Raviele, Simona Bassi, Lorenzo Preda, Giovanni Martinelli, Fedro A. Peccatori

Research output: Contribution to journalArticlepeer-review


Background: Lymphocyte-predominant Hodgkin disease (LPHD) differs in biology and clinical behaviour from classic Hodgkin disease. Almost 100% of LPHD neoplastic cells express CD20 and thus rituximab could be effective; yet limited data are available. Patients and Methods: We performed a retrospective analysis on patients with LPHD who were treated with rituximab at our institution to determine the magnitude of benefit offered by this drug. Results: Seven patients were identified; 4 received the drug as single agent while the rest received it in combination with chemotherapy. All except 2 received the drug in the salvage setting. Response rate was 100% with 6 of 7 patients achieving complete remission. At a median follow-up of 2 years, 4 patients are still disease free while the rest relapsed at a median time of 27 months. Conclusion: Rituximab is effective in LPHD and should be considered; however, the optimal schedule remains to be determined.

Original languageEnglish
Pages (from-to)26-29
Number of pages4
Issue number1
Publication statusPublished - Dec 2008


  • CD20
  • Lymphocyte-predominant Hodgkin disease
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Rituximab in lymphocyte-predominant Hodgkin disease'. Together they form a unique fingerprint.

Cite this